Erasca Inc. Common Stock vs Medpace Holdings Inc — how do they compare? Erasca Inc. Common Stock trades at $15.97 (market cap $5.40B), while Medpace Holdings Inc trades at $611.57 (market cap $16.82B). The key difference: Medpace Holdings Inc is far larger — about 3.1× Erasca Inc. Common Stock's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Erasca Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Erasca Inc. Common Stock for 0 Days and Medpace Holdings Inc for 14 Days on average.
| ERAS | MEDP | |
|---|---|---|
Market Cap | $5.40B | $16.82B |
Volume | 9,533,185 | 223,093 |
Sector | Health | Health |
52-Week High | $22.47 | $630.19 |
52-Week Low | $2.20 | $393.42 |
Typical Hold Time | 0 Days | 14 Days |
Enterprise Value | $5.18B | $16.44B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
MEDP trades at $612.05, up 1.29% today, near its consensus price target of $620.44. The stock shows strong profitability with a 17.67% net margin and has beaten earnings estimates for the last three quarters. Technical indicators are neutral overall, with support at $595 and resistance at $612. Recent news highlights CEO stock sales and institutional position changes, while the company prepares to report Q3 2026 results on October 21.
Outlook remains positive given consistent earnings beats and projected revenue growth to $2.8B in 2026. Risks include high valuation multiples (P/E 35.41) and insider selling. Analyst consensus is cautious with 79% hold ratings, suggesting limited near-term upside but solid fundamental support for long-term holders.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Erasca is a biotechnology company developing precision medicines for cancer. Its programs target genetic drivers of tumor growth.
Read more on ERAS →Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →